Nasus Pharma Ltd. (NSRX)

Nasus Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-5.86	-1.53	-1.05	-1.71
Loss (Gain) From Sale of Investments	0.95	0.44	-0.22	0.09
Stock-Based Compensation	0.45	0.01	0.04	0.02
Other Operating Activities	0.01	0.01	0.08	-0.41
Change in Accounts Payable	0.15	-0.01	-0.12	0.15
Change in Other Net Operating Assets	-0.57	0.41	0.28	0.33
Operating Cash Flow	-4.92	-0.67	-1.03	-1.21
Capital Expenditures	-0.01	-	-	-
Investment in Securities	-3	-	-	-
Other Investing Activities	-	-	-	-0.16
Investing Cash Flow	-3.01	-	-	-0.16
Short-Term Debt Issued	-	-	0.06	0.5
Total Debt Issued	-	-	0.06	0.5
Net Debt Issued (Repaid)	-	-	0.06	0.5
Issuance of Common Stock	8.92	1	1	0.97
Other Financing Activities	-	-0.23	-	-0.23
Financing Cash Flow	8.92	0.77	1.06	1.24
Foreign Exchange Rate Adjustments	-0.01	-0	0.01	-0.01
Net Cash Flow	0.98	0.1	0.04	-0.14
Free Cash Flow	-4.93	-0.67	-1.03	-1.21
Free Cash Flow Per Share	-0.62	-0.10	-0.15	-0.18
Levered Free Cash Flow	-3.04	-0.26	-0.54	-
Unlevered Free Cash Flow	-3.04	-0.24	-0.51	-
Change in Working Capital	-0.42	0.41	0.17	0.48

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q